Open AccessPatient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Author(s) -
А. Э. Багрий,
А. Д. Зубов,
M V Khomenko,
Е. С. Михайличенко,
Ekaterina Pylaeva,
Н. А. Хаустова,
Е. В. Брюховецкая
Publication year - 2021
Publication title -
rossijskij žurnal gastroènterologii, gepatologii, koloproktologii
Language(s) - English
Resource type - Journals
eISSN - 2658-6673
pISSN - 1382-4376
DOI - 10.22416/1382-4376-2021-31-2-14-26
Subject(s) - medicine , obeticholic acid , farnesoid x receptor , metformin , metabolic syndrome , liraglutide , fatty liver , sitagliptin , type 2 diabetes , type 2 diabetes mellitus , steatohepatitis , pioglitazone , cirrhosis , weight loss , gastroenterology , endocrinology , diabetes mellitus , disease , obesity , biochemistry , chemistry , receptor , nuclear receptor , transcription factor , gene , agonist
Aim. A current overview of non-pharmacological and drug-based approaches to non-alcoholic fatty liver disease (NAFLD) combined with type 2 diabetes mellitus (T2D). Key points. NAFLD is associated with an increased cardiovascular risk (due to association with “metabolic syndrome”) and the risks of liver cirrhosis and hepatocellular carcinoma. Macro- and microvascular complications in T2D comorbidity entail a higher overall mortality. A conjunction of lifestyle change and rational medication strategies to reach the target levels of glycosylated haemoglobin, low-density lipoprotein cholesterol, systolic and diastolic blood pressure is key in management of such patients. A body weight loss by 5–7 % or more (through caloric restriction or a bariatric surgery) promotes a marked reduction in liver fat and even reversal of steatohepatitis. Metered exercise exerts this effect even at insignificant weight loss. Minimising alcohol consumption and smoking is critical. A hepatotropic drug therapy is most essential in moderate fibrotic NAFLD. It includes antidiabetic agents (metformin, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors), bile acid preparations (e.g., 24-nor-ursodeoxycholic acid), farnesoid X receptor agonists (obeticholic acid, tropifexor), statins, acetylsalicylic acid. Combinations are superior to individual-drug schemes. Conclusion. The management of combined NAFLD-T2D requires a close inter-specialty involvement from hepatology, gastroenterology, endocrinology and cardiology. This interdisciplinary problem can be tackled through persuasive lifestyle recommendations and choosing rational medication strategies with a proved hepatoprotective efficacy.